Blueprint Medicines

Blueprint Medicines is harnessing the potential of the cancer genomics revolution by rapidly translating emerging insights into impactful drug programs. The proprietary Insights-to-Validation™ platform and chemical library are at the heart of its product development engine and enables the company to validate potential drivers of cancer and leverage these insights to develop genomically-tailored, highly specific therapies. Using this “molecular blueprint of cancer” to guide its efforts, Blueprint Medicines is committed to improving the lives of cancer patients by transforming genomically-defined subsets of cancer from life-threatening diseases to manageable conditions.

Read More
Spotlight
Blueprint Medicines was named oneof FierceBiotech'sFierce 15 -READ THE FULL ARTICLE HERE
5.08.12
Oncology Expert George Demetri, M.D., Joins Blueprint Medicines as a Clinical Advisor
read more >
1.24.12
Blueprint Medicines Appoints Oncology Drug Development Leader Christoph Lengauer as Chief Scientific Officer
read more >